Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
25M
-
Shares change
-
+2.64M
-
Total reported value, excl. options
-
$1.75B
-
Value change
-
+$228M
-
Put/Call ratio
-
0.46
-
Number of buys
-
110
-
Number of sells
-
-63
-
Price
-
$69.98
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q2 2020
203 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q2 2020.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25M shares
of 53M outstanding shares and own 47.16% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (4.01M shares), WELLINGTON MANAGEMENT GROUP LLP (2.03M shares), BlackRock Inc. (1.75M shares), VANGUARD GROUP INC (1.28M shares), KPS Global Asset Management UK Ltd (907K shares), 683 Capital Management, LLC (857K shares), WELLS FARGO & COMPANY/MN (831K shares), MORGAN STANLEY (763K shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (738K shares), and Antipodean Advisors LLC (656K shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.